Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2023 08:00 ET | Source: Gradalis, Inc.

Gradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing's Sarcoma

-Pilot study in Ewing's Sarcoma supports the therapeutic potential of Vigil in multiple solid tumor types- -Circulating tumor DNA levels, used to monitor therapeutic response, corresponded to changes...
February 02, 2023 08:01 ET | Source: Gradalis, Inc.

Gradalis to Present at the 2023 BIO CEO & Investor Conference

DALLAS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian...
December 14, 2022 08:00 ET | Source: Gradalis, Inc.

Gradalis Appoints Eric Hall as Chief Financial Officer

DALLAS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Gradalis, a privately-held, late-stage stage biotechnology company developing immunotherapies for ovarian and other cancers, today announced the appointment...
October 04, 2022 08:00 ET | Source: Gradalis, Inc.

Gradalis to Present at the 2022 Cell & Gene Meeting on the Mesa

DALLAS, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil®, today announced that...
October 03, 2022 08:00 ET | Source: Gradalis, Inc.

Gradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint Inhibitors

- In both studies, Gradalis’ lead program, Vigil, demonstrated a favorable safety profile when used in combination with checkpoint inhibitors, durvalumab or atezolizumab, without evidence of...
September 28, 2022 08:00 ET | Source: Gradalis, Inc.

Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®

-Webinar to feature presentations from Rodney Rocconi, M.D. and John Nemunaitis, M.D., on Monday, October 3rd at 1:00 p.m. ET DALLAS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Gradalis, a privately-held,...
August 29, 2022 08:05 ET | Source: Gradalis, Inc.

Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®

Analysis identified high expression of ENTPD1 gene in patients at baseline as a significant predictor of overall and recurrence-free survival following Vigil treatment, relative to placebo This...
June 02, 2022 08:58 ET | Source: Gradalis, Inc.

Gradalis Appoints Steven Engle as Chief Executive Officer

DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, announced today that Steven Engle has joined...
March 26, 2021 11:41 ET | Source: Gradalis, Inc.

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer

Results from pre-planned subgroup analysis of stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type (BRCA-wt) profile and homologous recombination proficiency (HRP) have been...
January 07, 2021 07:00 ET | Source: Gradalis, Inc.

Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology

The VITAL study, published in The Lancet Oncology, demonstrates that Vigil first-line maintenance treatment resulted in improved RFS in BRCA1/2-wt ovarian cancer when compared to placebo.Importantly...